Founded in 1934, Janus Henderson is a global investment management company that provides diverse mutual funds in equities, fixed-income and multi-asset strategies. Janus Henderson was created by the 2017 merger between Janus Capital Group and Henderson Global Investors and has $378.7 billion in assets under management, with more than 340 investment professionals working worldwide. Janus Henderson follows deep research, proprietary analysis and collaboration to find opportunities and manage risk in its investment approach. All these factors make it a reliable investment option.
We have chosen three Janus Henderson mutual funds — Janus Henderson Research JNRFX, Janus Henderson Global Life Sciences JNGLX and Janus Henderson Enterprise Fund JDMAX— that investors should buy now for the long term. These funds have a Zacks Mutual Fund Rank #1 (Strong Buy) or 2 (Buy), positive three-year and five-year annualized returns, minimum initial investments within $5000 and expense ratios considerably lower than the category average. So, these funds have provided a comparatively stronger performance and carry a lower fee.
Janus Henderson Research fund seeks to generate additional income by lending up to one-third of its total assets to qualified broker-dealers and institutions, either on a short-term or long-term basis, as determined at loan origination. JNRFX invests in common stocks for growth potential, ranging from large companies to small and emerging firms.
Joshua Cummings has been the lead manager of JNRFX since Jan. 26, 2024. Most of the fund’s holdings were in companies such as NVIDIA Corp (12.3%), Microsoft Corp (11.4%) and Apple Inc. (6.9%) as of Sept. 30, 2024.
JNRFX’s 3-year and 5-year returns are 15.2% and 17.5%, respectively. Its annual expense ratio is 0.67%. JNRFX has a Zacks Mutual Fund Rank #1.
To see how this fund performed compared to its category and other 1 and 2 Ranked Mutual Funds, please click here.
Janus Henderson Global Life Sciences fund primarily invests in equity securities issued by companies engaged in life sciences orientation.
Andy Acker has been the lead manager of JNGLX since May 1, 2007. Most of the fund’s holdings were in companies like Eli Lilly and Co (9%), UnitedHealth Group Inc. (6.6%) and Novo Nordisk A/S (3.7%) as of Dec. 31, 2024.
JNGLX’s 3-year and 5-year returns are 7.8% and 10.8%, respectively. Its annual expense ratio is 0.80%. JNGLX has a Zacks Mutual Fund Rank #1.
Janus Henderson Enterprise Fund invests most of its assets in equity assets of mid-sized companies. JDMAX advisors also invest in foreign securities.